AGU PUNT SL

AGU PUNT SL specializes in dry-needling needles, such as the AGUPUNT APS and AGUPUNT IPEN models. These devices are specifically designed for medical dry-needling procedures, which are used in myofascial release and trigger point therapy. The focus is on a single category of devices, ensuring precision for targeted therapeutic applications.

AGU PUNT SL is based in the United States. The company’s location in the US aligns with regulatory frameworks applicable to its medical devices, including compliance with FDA requirements for Class II devices.

AGU PUNT SL’s dry-needling needles are listed in the FDA’s Unique Device Identification (UDI) database. This registry ensures traceability and transparency in the medical device supply chain, allowing healthcare providers and regulators to verify device details and compliance.

AGU PUNT SL’s dry-needling needles fall under Class II medical device classification. This classification is typically assigned to devices that pose moderate risk and require special controls to ensure safety and effectiveness, such as pre-market notifications and post-market surveillance.